Avantika Dhadwal, Ankita Rana, Sakshi Sharma, Gaurav Bhardwaj
Avantika Dhadwal*, Ankita Rana, Sakshi Sharma, Gaurav Bhardwaj
Department of Pharmaceutics, Himachal Institute of Pharmaceutical Education and Research, Nadaun.
Volume - 15,
Issue - 4,
Year - 2023
After being identified as a Paramyxoviridae member in 1999, NiV has been linked to encephalitis epidemics in Bangladesh, Malaysia, Singapore, the Philippines, and India. NiV has a case-fatality rate of 100% and can cause fever encephalitis and severe respiratory disease in people. In addition to supportive care, there are no authorised vaccinations or therapies. Histopathology, IgG/IgM/antigen ELISA, immunofluorescence assay, nucleic acid amplification testing (NAAT), viral isolation, and neutralisation testing are among the laboratory tests used to detect NiV. According to research done with thermal sensors, P. giganteus bats use date palm sap plants and consume the sap as it is being gathered. Nipah virus is believed to be the next pandemic agent, and Corona virus safety measures have helped to reduce its spread in Kerala. It is a respiratory illness that does not cause loss of taste or smell, but has a high death rate (40-45%). NiV patients have highest infectious potential during symptomatic phases, and exposure to the bodily fluids of infected individuals appears to be a viable route for human-to-human transmission. NiV epidemics are highly effective due to their rapid transmission through nosocomial and zoonotic mechanisms. Ribavirin was considered as the first antiviral medication which is used in the treatment of NiV, but ribavirin decreased mortality toll by 36%. Clinical studies with the purine analogue favipirivir (T-705) blocking RNA-dependent RNA polymerase have been conducted for the treatment of Ebola, and different influenza antiviral medications have also demonstrated effectiveness against NiV in Syrian hamster animal models. Preclinical research has demonstrated full protection.
Cite this article:
Avantika Dhadwal, Ankita Rana, Sakshi Sharma, Gaurav Bhardwaj. A Comprehensive Review on Nipah Virus Infection: Classification, Epidemiology, Treatment and Prevention. Research Journal of Pharmacology and Pharmacodynamics.2023;15(4):223-0. doi: 10.52711/2321-5836.2023.00039
Avantika Dhadwal, Ankita Rana, Sakshi Sharma, Gaurav Bhardwaj. A Comprehensive Review on Nipah Virus Infection: Classification, Epidemiology, Treatment and Prevention. Research Journal of Pharmacology and Pharmacodynamics.2023;15(4):223-0. doi: 10.52711/2321-5836.2023.00039 Available on: https://rjppd.org/AbstractView.aspx?PID=2023-15-4-13
1. Ang BSP, Lim TCC, Wang L. Nipah virus infection. J Clin Microbial. 2018; 56(6): e01875–17. DOI: https://doi.org/10.1128/JCM.01875-17
2. World Health Organization (17 February 2023). Disease Outbreak News; Nipah virus disease – Bangladesh. Available at https://www.who.int/emergencies/disease-outbreak-news/item/2023-DON442
3. B. S. P. Ang, T. C. C. Lim, L. Wang, Nipah virus infection. J. Clin. Microbial. 56, e01875–e01817 (2018).
4. S. A. Rahman et al.; Henipaviral Ecology Research Group, Risk factors for Nipah virus infection among pteropid bats, Peninsular Malaysia. Emerge. Infect. Dis. 19, 51–60 (2013).
5. E. de Wit, V. J. Munster, Animal models of disease shed light on Nipah virus pathogenesis and transmission. J. Pathol. 235, 196–205 (2015).
6. Tan KS, Tan CT, Goh KJ. 1999. Epidemiological aspects of Nipah virus infection. Neurol J South East Asia 4:77– 81.
7. Harit AK, Ichhpujani RL, Gupta S, et al. Nipah/Hendra virus outbreak in Siliguri, West Bengal, India in 2001. Indian J Med Res. 2006; 123(4): 553–560.
8. Arankalle VA, Bandyopadhyay BT, Ramdasi AY, et al. Genomic characterization of Nipah virus, West Bengal, India. Emerge Infect Dis. 2011; 17(5): 907–909. DOI: https://doi.org/10.3201/eid1705.100968
9. Chua KB, Goh KJ, Wong KT et al. Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia. Lancet 1999; 354:1257–9.
10. 5 Johnson K, Vu M, Freiberg AN. Recent advances in combating Nipah virus. Fac Rev 2021; 10:74.
11. Fogarty R, Halpin K, Hyatt AD, Daszak P, Mungall BA. Henipavirus susceptibility to environmental variables, Virus Res, 2008, vol. 132 (pg. 140-4)
12. Gurley ES, Montgomery JM, Hossain MJ, et al. Person-to-person transmission of Nipah virus in a Bangladeshi community, Emerg Infect Dis, 2007, vol. 13 (pg. 1031-7)
13. Chua KB, Bellini WJ, Rota PA, et al. Nipah virus: a recently emergent deadly paramyxovirus. Science 2000; 288:1432–5.doi:10.1126/science.288.5470.1432
14. Epstein JH, Field HE, Luby S, et al. Nipah virus: impact, origins, and causes of emergence. Curr Infect Dis Rep 2006; 8:59–65.doi:10.1007/s11908-006-0036-2
15. WHO, 2017. R&D Blueprint for action to prevent epidemics. WHO RD Bluepr. http://www.who.int/blueprint/en/ (accessed 12 Sep 2017).
16. Chua KB, Gubler Bellini WJ, Rota PA, Harcourt BH, Tamin A, Lam SK, Ksiazek TG, Rollin PE, Zaki SR, Shieh W, Goldsmith CS, DJ, Roehrig JT, Eaton B, Gould AR, Olson J, Field H, Daniels P, Ling AE, Peters CJ, Anderson LJ, Mahy BW. 2000. Nipah virus: a recently emergent deadly paramyxovirus. Science 288:1432–1435.
17. WHO, 2018. Nipah Virus (NiV) Infection. http://www.who.int/csr/ disease/nipah/en/ (accessed 25 Feb 2018).
18. CDC, 2018. Nipah Virus (NiV). https://www.cdc.gov/vhf/nipah/ index.html (accessed 25 Feb 2018).
19. Sejvar JJ, Hossain J, Saha SK, Gurley ES, Banu S, Hamadani JD, et al. Long-term neurological and functional outcome in Nipah virus infection. Ann Neurol 2007; 62:235-42.
20. Chang LY, MohdAli AR, Sharifah SH, AbuBakar S. Quantitative estimation of Nipah virus replication kinetics in vitro. Virol J 2006; 3:47.
21. Chang LY, MohdAli AR, Sharifah SH, AbuBakar S. Nipah virus RNA synthesis in cultured pig and 8human cells. J Med Virol 2006; 78:1105-12
22. Duprex WP, McQuaid S, Hangartner L, Billeter MA, Rima BK. Observation of measles virus cell-to-cell spread in astrocytoma cells by using a green fluorescent protein-expressing recombinant virus. J Virol 1999; 73:9568-75.
23. Firsching R, Buchholz CJ, Schneider U, Cattaneo R, ter Meulen V, Schneider-Schaulies J. Measles virus spread by cell-cell contacts: uncoupling of contact-mediated receptor (CD46) downregulation from virus uptake. J Virol 1999; 73:5265-73.
24. Goh KJ, Tan CT, Chew NK, et al. Clinical features of Nipah virus encephalitis among pig farmers in Malaysia. N Engl J Med 2000; 342:1229-35.
25. Wong KT, Shieh WJ, Kumar S, et al. Pathology and pathogenesis of an emerging paramyxoviral zoonosis. Am J Pathol 2002; 161:2153-67.
26. World Health Organization (2009) Nipah virus. Media Center. Fact sheet 262.
27. Hossain MJ, Gurley ES, Montgomery JM, Bell M, Carroll DS, et al. (2008) Clinical presentation of nipah virus infection in Bangladesh. Clin Infect Dis 46:977-984.
28. World Organisation for Animal Health (Office International des Epizooties’: OIE) (2009) Nipah (virus encephalitis). Technical Disease Cards, OIE, Paris.
29. Daniels P, Ksiazek T, Eaton BT. Laboratory diagnosis of Nipah and Hendra virus infections. Microbes Infect 2001; 3:289–95.doi:10.1016/S1286-4579(01)01382-X
30. Kulkarni DD, Tosh C, Venkatesh G, et al. Nipah virus infection: current scenario. Indian J Virol 2013; 24:398–408.doi:10.1007/s13337-013-0171-y
31. Wang LF, Daniels P. Diagnosis of henipavirus infection: current capabilities and future directions. Curr Top Microbiol Immunol 2012; 359:179–96.doi:10.1007/82_2012_215
32. Khan M, Nahar N, Sultana R, Hossain M, Gurley ES, Luby S., Understanding bats access to date palm sap: identifying preventative techniques for Nipah virus transmission, 2008New Orleans American Society of Tropical Medicine and Hygienepg. 331
33. Fogarty R, Halpin K, Hyatt AD, Daszak P, Mungall BA. Henipavirus susceptibility to environmental variables, Virus Res, 2008, vol. 132 (pg. 140-4)
34. Hsu VP, Hossain MJ, Parashar UD, et al. Nipah virus encephalitis reemergence, Bangladesh, Emerg Infect Dis, 2004, vol. 10 (pg. 2082-7)
35. Montgomery JM, Hossain MJ, Gurley E, et al. Risk factors for Nipah virus encephalitis in Bangladesh, Emerg Infect Dis, 2008, vol. 14 (pg. 1526-32)
36. Hossain MJ, Gurley ES, Montgomery JM, et al. Clinical presentation of nipah virus infection in Bangladesh. Clin Infect Dis 2008; 46:977–84.doi:10.1086/529147
37. Hsu VP, Hossain MJ, Parashar UD, et al. Nipah virus encephalitis reemergence, Bangladesh. Emerg Infect Dis 2004; 10:2082–7.doi:10.3201/eid1012.040701
38. Chan YP, Chua KB, Koh CL, et al. Complete nucleotide sequences of Nipah virus isolates from Malaysia. J Gen Virol 2001;82(Pt 9):2151–5.doi:10.1099/0022-1317-82-9-2151
39. Gurley ES, Montgomery JM, Hossain MJ, et al. Person-to-person transmission of Nipah virus in a Bangladeshi community. Emerg Infect Dis 2007; 13:1031–7.doi:10.3201/eid1307.061128
40. Luby SP, Hossain MJ, Gurley ES, et al. Recurrent zoonotic transmission of Nipah virus into humans, Bangladesh, 2001–2007. Emerg Infect Dis 2009; 15:1229–35.doi:10.3201/eid1508.081237
41. Hassan MZ, Sazzad HMS, Luby SP, et al. Nipah virus contamination of hospital surfaces during outbreaks, Bangladesh, 2013–2014. Emerg Infect Dis 2018; 24:15–21.doi:10.3201/eid2401.161758
42. Chua KB, Lam SK, Goh KJ, et al. The presence of Nipah virus in respiratory secretions and urine of patients during an outbreak of Nipah virus encephalitis in Malaysia. J Infect. 2001; 42:40–3.
43. Harcourt BH, Lowe L, Tamin A, et al. Genetic characterization of Nipah virus, Bangladesh, 2004. Emerg Infect Dis. 2005; 11:1594–7.
44. Hadley MB, Blum LS, Mujaddid S, et al. Why Bangladeshi nurses avoid ‘nursing’: social and structural factors on hospital wards in Bangladesh. Soc Sci Med. 2007; 64:1166–77.
45. Blum LS, Khan R, Nahar N, Breiman RF. In-depth assessment of an outbreak of Nipah encephalitis with person-to-person transmission in Bangladesh: implications for prevention and control strategies. Am J Trop Med Hyg. 2009; 80:96–102.
46. Luby S, Hossain J, Gurley E, et al. Recurrent zoonotic transmission of Nipah virus into humans, Bangladesh, 2001–2007. Emerg Infect Dis. 2009; 15:1229–35.
47. WHO (2018) WHO | Nipah Virus Infection. World Health Organization. Available at http://www.who.int/csr/disease/nipah/en/ (Accessed 17 June 2018)
48. NIPAH Virus Disease Guidelines: National Centre for Disease Control (NCDC). Available at http://www.ncdc.gov.in/index4.php?lang=1&level=0&linkid=113&lid=228 (Accessed 17 June 2018)
49. Uwishema, O., Wellington, J., Berjaoui, C., Muoka, K.O., Onyeaka, C.V.P. and Onyeaka, H., 2022. A short communication of Nipah virus outbreak in India: An urgent rising concern. Annals of Medicine and Surgery, 82, p.104599.
50. Hsu VP, Hossain MJ, Parashar UD, et al. Nipah virus encephalitis reemergence, Bangladesh. Emerg Infect Dis 2004; 10:2082–7.
51. Sejvar JJ, Hossain J, Saha SK, et al. Long-term neurological and functional outcome in Nipah virus infection. Ann Neurol 2007; 62:235–42.
52. Tan CT, Goh KJ, Wong KT, Sarji SA, Chua KB, Chew NK, Murugasu P, Loh YL, Chong HT, Tan KS, Thayaparan T, Kumar S, Jusoh MR. 2002. Relapsed and late-onset Nipah encephalitis. Ann Neurol 51:703–708. https://doi.org/10.1002/ana.10212.
53. Harcourt BH, Tamin A, Ksiazek TG, et al. Molecular characterization of Nipah virus, a newly emergent paramyxovirus. Virology 2000; 271:334–49.
54. Marsh GA, de Jong C, Barr JA, et al. Cedar virus: a novel Henipavirus isolated from Australian bats. PLoS Pathog 2012;8: e1002836.
55. Wang L, Harcourt BH, Yu M, et al. Molecular biology of Hendra and Nipah viruses. Microbes Infect 2001; 3:279–87.
56. de Araujo J, Lo MK, Tamin A, et al. Antibodies against Henipa-like viruses in Brazilian bats. Vector-Borne and Zoonotic Diseases2017; 17:271–4.
57. WHO, 2018. Nipah Virus Infection factsheet. http://www.who.int/mediacentre/factsheets/fs262/en/ (accessed 25 Jan 2018).
58. Hossain MJ, Gurley ES, Montgomery JM, et al. Clinical presentation of nipah virus infection in Bangladesh. Clin Infect Dis2008; 46:977–84.
59. Hsu VP, Hossain MJ, Parashar UD, et al. Nipah virus encephalitis reemergence, Bangladesh. Emerg Infect Dis 2004; 10:2082–7.
60. Hegde ST et al. (2016) Investigating rare risk factors for Nipah virus in Bangladesh: 2001–2012. EcoHealth 13, 720–728.
61. Ambat, A.S.; Zubair, S.M.; Prasad, N.; Pundir, P.; Rajwar, E.; Patil, D.S.; Mangad, P. Nipah virus: A review on epidemiological characteristics and outbreaks to inform public health decision making. J. Infect. Public Health 2019, 12, 634–639.
62. Paton, N.I.; Leo, Y.S.; Zaki, S.R.; Auchus, A.P.; Lee, K.E.; Ling, A.E.; Chew, S.K.; Ang, B.; Rollin, P.E.; Umapathi, T.; et al. Outbreak of Nipah-virus infection among abattoir workers in Singapore. Lancet 1999, 354, 1253–1256.
63. Chong, H.T.; Kamarulzaman, A.; Tan, C.T.; Goh, K.J.; Thayaparan, T.; Kunjapan, S.R.; Chew, N.K.; Chua, K.B.; Lam, S.K. Treatment of acute Nipah encephalitis with ribavirin. Ann. Neurol. 2001, 49, 810–813.
64. Broder, C.C. Henipavirus outbreaks to antivirals: The current status of potential therapeutics. Curr. Opin. Virol. 2012, 2, 176–187.
65. Freiberg, A.N.; Worthy, M.N.; Lee, B.; Holbrook, M.R. Combined chloroquine and ribavirin treatment does not prevent death in a hamster model of Nipah and Hendra virus infection. J. Gen. Virol. 2010, 91, 765–772.
66. Dawes, B.E.; Kalveram, B.; Ikegami, T.; Juelich, T.; Smith, J.K.; Zhang, L.; Park, A.; Lee, B.; Komeno, T.; Furuta, Y.; et al. Favipiravir (T-705) protects against Nipah virus infection in the hamster model. Sci. Rep. 2018, 8, 7604.
67. Escaffre, O.; Hill, T.; Ikegami, T.; Juelich, T.L.; Smith, J.K.; Zhang, L.; Perez, D.E.; Atkins, C.; Park, A.; Lawrence, W.S.; et al. Experimental Infection of Syrian Hamsters with Aerosolized Nipah Virus. J. Infect. Dis. 2018, 218, 1602–1610.
68. Paton, N.I.; Leo, Y.S.; Zaki, S.R.; Auchus, A.P.; Lee, K.E.; Ling, A.E.; Chew, S.K.; Ang, B.; Rollin, P.E.; Umapathi, T.; et al. Outbreak of Nipah-virus infection among abattoir workers in Singapore. Lancet 1999, 354, 1253–1256
69. Srinivasan, K.; Rao, M. Understanding the clinical utility of favipiravir (T-705) in coronavirus disease of 2019: A review. Ther. Adv. Infect. Dis. 2021, 8, 204993612110630. [Google Scholar] [CrossRef] [PubMed]
70. Dawes, B.E.; Kalveram, B.; Ikegami, T.; Juelich, T.; Smith, J.K.; Zhang, L.; Park, A.; Lee, B.; Komeno, T.; Furuta, Y.; et al. Favipiravir (T-705) protects against Nipah virus infection in the hamster model. Sci. Rep. 2018, 8, 7604.
71. Georges-Courbot, M.C.; Contamin, H.; Faure, C.; Loth, P.; Baize, S.; Leyssen, P.; Neyts, J.; Deubel, V. Poly(I)-poly(C12U) but not ribavirin prevents death in a hamster model of Nipah virus infection. Antimicrob. Agents Chemother. 2006, 50, 1768–1772.
72. Bossart KN, Ruck B, Feldmann F, Brining D, Scott D, LaCasse R, et al. A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge. Sci Transl Med 2012;4:146-7.
73. Broder CC, Xu K, Nikolov DB, Zhu Z, Dimitrov DS, Middleton D, et al. A treatment for and vaccine against the deadly Hendra and Nipah viruses. Antivir Res 2013; 100:8-13.
74. Pickering BS, Hardham JM, Smith G, Weingartl ET, Dominowski PJ, Foss DL, et al. Protection against Henipaviruses in swine requires both, cell-mediated and humoral immune response. Vaccine 2016; 34:4777-86.
75. Weingartl HM, Berhane Y, Caswell JL, Loosmore S, Audonnet JC, Roth JA, et al. Recombinant Nipah virus vaccines protect pigs against challenge. J Virol 2006;80:7929-38.
76. Sen, B.; Dhimal, M.; Latheef, A.T.; Ghosh, U. Climate change: Health effects and response in South Asia. BMJ 2017, 359, j5117
77. Mondal, M.S.H. The implications of population growth and climate change on sustainable development in Bangladesh. Jamba 2019, 11, 535
78. Ang, B.S.P.; Lim, T.C.C.; Wang, L. Nipah Virus Infection. J. Clin. Microbiol. 2018, 56
79. Olivero, J.; Fa, J.E.; Real, R.; Marquez, A.L.; Farfan, M.A.; Vargas, J.M.; Gaveau, D.; Salim, M.A.; Park, D.; Suter, J.; et al. Recent loss of closed forests is associated with Ebola virus disease outbreaks. Sci. Rep. 2017, 7,14291
80. Chua, K.B.; Chua, B.H.; Wang, C.W. Anthropogenic deforestation, El Nino and the emergence of Nipah virus in Malaysia. Malays. J. Pathol. 2002, 24, 15–21.
81. Chua, K.B. Risk factors, prevention and communication strategy during Nipah virus outbreak in Malaysia.Malays. J. Pathol. 2010, 32, 75–80.
82. Plowright, R.K.; Eby, P.; Hudson, P.J.; Smith, I.L.; Westcott, D.; Bryden, W.L.; Middleton, D.; Reid, P.A.; McFarlane, R.A.; Martin, G.; et al. Ecological dynamics of emerging bat virus spillover. Proc. Biol. Sci. 2015,282, 20142124.
83. Khan SU et al. (2012) A randomized controlled trial of interventions to impede date palm sap contamination by bats to prevent Nipah virus transmission in Bangladesh. PloS ONE 7, e42689.
84. Hassan MZ et al. (2018) Nipah virus contamination of hospital surfaces during outbreaks, Bangladesh, 2013–2014. Emerging Infectious Diseases 24, 15–21.
85. Satterfield BA, Dawes BE, Milligan GN. 2016. Status of vaccine research and development of vaccines for Nipah virus. Vaccine 34:2971–2975.